Drug Trial Radar · NCT05047770
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,013
Actual
Start
Oct 7, 2021
Primary completion
Aug 29, 2022
Study completion Aug 31, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Conditions
- Herpes Zoster
Interventions
HZ/suBiological
2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
Flu D-QIVCombination product
1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
mRNA-1273Biological
1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group RatiosTime frame: At 1 month post-dose 2 of HZ/su vaccine administration (Week 14 for HZ/suSeq group and Week 12 for HZ/suCoAd group)
- Anti-S Protein Antibody Concentrations Expressed as GMCs in HZ/suSeq and HZ/suCoAd Groups, and Between-group RatiosTime frame: At 1 month post-mRNA-1273 booster dose administration (Week 4 for both HZ/suSeq and HZ/suCoAd groups)
- Anti-hemagglutinin Inhibition (HI) Antibody Titers Expressed as Geometric Mean Titers (GMTs) Against the 4 Influenza Strains in Flu D-QIV Vaccine in FluD-QIVSeq and FluD-QIVCoAd Groups, and Between-group RatiosTime frame: At 1 month post-Flu D-QIV vaccine dose administration (Week 6 for FluD-QIVSeq group and Week 4 for FluD-QIVCoAd group)
- Anti-S Protein Antibody Concentrations Expressed as GMCs in FluD-QIVSeq and FluD-QIVCoAd Groups, and Between-group RatiosTime frame: At 1 month post-mRNA-1273 booster dose administration (Week 4 for both FluD-QIVSeq and FluD-QIVCoAd groups)
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Tempe, Arizona
GSK Investigational Site
Oxnard, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Atlantis, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
El Dorado, Kansas
GSK Investigational Site
Newton, Kansas
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Biloxi, Mississippi
GSK Investigational Site
Fremont, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Berlin, New Jersey
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Norman, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Yukon, Oklahoma
GSK Investigational Site
Grants Pass, Oregon
GSK Investigational Site
Anderson, South Carolina
GSK Investigational Site
Columbia, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Beaumont, Texas
GSK Investigational Site
Cedar Park, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
San Antonio, Texas
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.